Proteus Sustained Behavior Change Study
Primary Purpose
Type 2 Diabetes Mellitus
Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Proteus Sustained Behavior Change system
Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Self-reported diagnosis of Type 2 Diabetes Mellitus within the past 2-12 months
- Hemoglobin A1c ≥7.5 and ≤11, obtained with the point-of-care HbA1c diagnostic device during the enrollment visit
- Self-reported current use of metformin for Type 2 diabetes
- Male or female ≥ 18
- Outpatient
- Self-reported capacity to perform "moderate" exercise, as specified by in the 2010 joint American College of Sports Medicine/American Diabetes Association guidelines
- Designation of one caregiver to be involved in the study for its entire duration. A caregiver can be a relative, friend, or trained or untrained hired individual.
- Self-reported mobile phone reception at home and/or at work
- Willingness to adhere to study procedures, including troubleshooting of the Raisin System by a third-party if needed. The third party will be blinded to any personal subject identifiers.
- Capacity to read and speak English proficiently, as judged by the investigator during the screening interview
- Capacity to understand the instructions for the study, as judged by the investigator during the screening interview
Exclusion Criteria:
- Self-reported treatment with metformin for less than 2 months at the time of screening
- Self-reported adverse reaction to metformin (e.g., ongoing nausea, vomiting, bloating, diarrhea) or to other concomitant medications being administered at the time of screening
- Self-reported use of injectable hypoglycemic agents, such as insulin, exenatide, liraglutide or pramlintide
- Physical or medical condition that could prevent safe participation in moderate levels of physical activity, as surveyed by the Physical Activity Readiness Questionnaire (PAR-Q) and interpreted by the investigator
- Inability to use a mobile phone (e.g., to find icons or to open and to read a SMS), or inability to operate the approved glucometer that will be provided for use in the study
- Self-reported current (i.e., in the last 12 months) alcohol or drug abuse (including, but not limited, to use of marijuana)
- Positive urine pregnancy test for women
- Women of child bearing potential who are not using a medically accepted means of contraception. Accepted means of contraception include oral contraceptive or implant, condom, diaphragm, spermicide, intrauterine device, tubal ligation, or partner with vasectomy
- Self-reported history of myocardial infarction within past 60 days
- Self-reported history of cerebral vascular accident within past 60 days
- Self-reported history of skin sensitivity to adhesive medical tape or metals
- Self-reported history of acute or chronic dermatitis, excluding atopic dermatitis
- Self-reported allergies that could preclude safe participation in the study
- Current participation in another clinical study, or participation in a clinical study in the past 30 days during which an investigational device or drug was used
- Any condition that, in the investigator's opinion, would preclude the subject's being able to meet all of the protocol requirements, or would compromise the subject's safety during participation in the study
- Presence of cognitive impairment, as judged by the investigator during the screening interview
- Inability to provide informed consent for any reason
Sites / Locations
- Northwestern University
- Center for Connected Health, Partners Healthcare
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Sustained Behavior Change system support
Control
Arm Description
Outcomes
Primary Outcome Measures
Self-efficacy
As measured by the 13-item self-efficacy expectancies and outcomes expectancies sub-scale of the Multidimensional Diabetes Questionnaire
Secondary Outcome Measures
Perceived effectiveness of caregiver support
As measured by the 12-item positive reinforcing behaviors and misguided support sub-scale of the Multidimensional Diabetes Questionnaire
Diabetes-related distress
As measured by the 20-item Problem Areas In Diabetes scale
At-home measurements of fasting glucose
Weekly average for each time point
In-clinic measurements of fasting glucose
Discrete lab measurement
Usability
Device-related and -unrelated adverse events
Full Information
NCT ID
NCT01503008
First Posted
December 28, 2011
Last Updated
March 1, 2013
Sponsor
Proteus Digital Health, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT01503008
Brief Title
Proteus Sustained Behavior Change Study
Official Title
Proteus Sustained Behavior Change Study
Study Type
Interventional
2. Study Status
Record Verification Date
March 2013
Overall Recruitment Status
Withdrawn
Study Start Date
February 2012 (undefined)
Primary Completion Date
August 2012 (Anticipated)
Study Completion Date
August 2012 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Proteus Digital Health, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The study will test whether the Proteus Sustained Behavior Change (SBC) System will help Type 2 diabetics feel more able to perform self-care activities, feel less distressed about diabetes, and reduce mean fasting blood glucose levels. The SBC system uses ingestible and wearable sensing devices and mobile phones to reinforce positive behaviors around medication usage, exercise and rest.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sustained Behavior Change system support
Arm Type
Experimental
Arm Title
Control
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Proteus Sustained Behavior Change system
Intervention Description
The SBC system uses ingestible and wearable sensing devices and mobile phones to reinforce positive behaviors around medication usage, exercise and rest. Subjects will be taking their regularly prescribed oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors); glucometer
Intervention Type
Drug
Intervention Name(s)
Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)
Intervention Description
Oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors) at subjects' regularly prescribed doses; glucometer
Primary Outcome Measure Information:
Title
Self-efficacy
Description
As measured by the 13-item self-efficacy expectancies and outcomes expectancies sub-scale of the Multidimensional Diabetes Questionnaire
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Perceived effectiveness of caregiver support
Description
As measured by the 12-item positive reinforcing behaviors and misguided support sub-scale of the Multidimensional Diabetes Questionnaire
Time Frame
3 months
Title
Diabetes-related distress
Description
As measured by the 20-item Problem Areas In Diabetes scale
Time Frame
3 months
Title
At-home measurements of fasting glucose
Description
Weekly average for each time point
Time Frame
1, 6, 12 weeks
Title
In-clinic measurements of fasting glucose
Description
Discrete lab measurement
Time Frame
0, 6, 12 weeks
Title
Usability
Time Frame
3 months
Title
Device-related and -unrelated adverse events
Time Frame
Up to 4 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Self-reported diagnosis of Type 2 Diabetes Mellitus within the past 2-12 months
Hemoglobin A1c ≥7.5 and ≤11, obtained with the point-of-care HbA1c diagnostic device during the enrollment visit
Self-reported current use of metformin for Type 2 diabetes
Male or female ≥ 18
Outpatient
Self-reported capacity to perform "moderate" exercise, as specified by in the 2010 joint American College of Sports Medicine/American Diabetes Association guidelines
Designation of one caregiver to be involved in the study for its entire duration. A caregiver can be a relative, friend, or trained or untrained hired individual.
Self-reported mobile phone reception at home and/or at work
Willingness to adhere to study procedures, including troubleshooting of the Raisin System by a third-party if needed. The third party will be blinded to any personal subject identifiers.
Capacity to read and speak English proficiently, as judged by the investigator during the screening interview
Capacity to understand the instructions for the study, as judged by the investigator during the screening interview
Exclusion Criteria:
Self-reported treatment with metformin for less than 2 months at the time of screening
Self-reported adverse reaction to metformin (e.g., ongoing nausea, vomiting, bloating, diarrhea) or to other concomitant medications being administered at the time of screening
Self-reported use of injectable hypoglycemic agents, such as insulin, exenatide, liraglutide or pramlintide
Physical or medical condition that could prevent safe participation in moderate levels of physical activity, as surveyed by the Physical Activity Readiness Questionnaire (PAR-Q) and interpreted by the investigator
Inability to use a mobile phone (e.g., to find icons or to open and to read a SMS), or inability to operate the approved glucometer that will be provided for use in the study
Self-reported current (i.e., in the last 12 months) alcohol or drug abuse (including, but not limited, to use of marijuana)
Positive urine pregnancy test for women
Women of child bearing potential who are not using a medically accepted means of contraception. Accepted means of contraception include oral contraceptive or implant, condom, diaphragm, spermicide, intrauterine device, tubal ligation, or partner with vasectomy
Self-reported history of myocardial infarction within past 60 days
Self-reported history of cerebral vascular accident within past 60 days
Self-reported history of skin sensitivity to adhesive medical tape or metals
Self-reported history of acute or chronic dermatitis, excluding atopic dermatitis
Self-reported allergies that could preclude safe participation in the study
Current participation in another clinical study, or participation in a clinical study in the past 30 days during which an investigational device or drug was used
Any condition that, in the investigator's opinion, would preclude the subject's being able to meet all of the protocol requirements, or would compromise the subject's safety during participation in the study
Presence of cognitive impairment, as judged by the investigator during the screening interview
Inability to provide informed consent for any reason
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kamal Jethwani, MD
Organizational Affiliation
Center for Connected Health, Partners Healthcare
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Michael J Coons, PhD
Organizational Affiliation
Northwestern University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Bonnie Spring, PhD
Organizational Affiliation
Northwestern University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Northwestern University
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
Center for Connected Health, Partners Healthcare
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Proteus Sustained Behavior Change Study
We'll reach out to this number within 24 hrs